COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021 Post published:November 9, 2021 Post category:Press Release
COMPASS Pathways Shares Positive Topline Results from Phase 2b COMP360 Study Post published:November 9, 2021 Post category:Press Release
Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021 Post published:November 8, 2021 Post category:Press Release
Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health Post published:November 8, 2021 Post category:Press Release
PharmaDrug Advances Psychedelics Program with Analogue DMT Formulations to Treat Eye Diseases Post published:November 5, 2021 Post category:Press Release
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board Post published:November 5, 2021 Post category:Press Release
Cybin Granted DEA Schedule I Manufacturing License Post published:November 4, 2021 Post category:Press Release
MINDCURE Provides Update on Studies and Clinical Trials Post published:November 4, 2021 Post category:Press Release
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for PTSD Post published:November 3, 2021 Post category:Press Release
Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients Post published:November 3, 2021 Post category:Press Release